1:59 PM
Apr 15, 2019
 |  BC Extra  |  Company News

Supreme Court decision signals likely end to Allergan sovereign immunity gambit

A lower court's ruling that a sovereign entity cannot assert immunity to shield a patent from inter partes review (IPR) will stand, as the U.S. Supreme Court rejected a petition from Allergan and the Saint Regis Mohawk Tribe to review the ruling Monday. While SCOTUS's decision likely marks the end of the road for Allergan's attempt to circumvent Patent Trial and Appeal Board (PTAB) review, the high court could still weigh in...

Read the full 336 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >